Rui  Avelar net worth and biography

Rui Avelar Biography and Net Worth

Insider of Evolus
Rui Avelar, M.D., has served as our Chief Medical Officer, and as the Chief Medical Officer of ALPHAEON, since January 2014. From March 2011 to December 2013, he served as Chief Medical Officer of Allergan Medical, where he was responsible for clinical development, clinical operations, safety, medical writing, biostatistics and regulatory matters. Dr. Avelar holds a M.D. from the University of Toronto and has received training accreditation in Sports Medicine from the Canadian Academy of Sports Medicine.

What is Rui Avelar's net worth?

The estimated net worth of Rui Avelar is at least $3.96 million as of March 19th, 2024. Dr. Avelar owns 372,288 shares of Evolus stock worth more than $3,961,144 as of June 19th. This net worth estimate does not reflect any other investments that Dr. Avelar may own. Additionally, Dr. Avelar receives a salary of $823,190.00 as Insider at Evolus. Learn More about Rui Avelar's net worth.

How old is Rui Avelar?

Dr. Avelar is currently 62 years old. There are 2 older executives and no younger executives at Evolus. Learn More on Rui Avelar's age.

What is Rui Avelar's salary?

As the Insider of Evolus, Inc., Dr. Avelar earns $823,190.00 per year. The highest earning executive at Evolus is Mr. David Moatazedi, President, CEO & Director, who commands a salary of $1,750,000.00 per year. Learn More on Rui Avelar's salary.

How do I contact Rui Avelar?

The corporate mailing address for Dr. Avelar and other Evolus executives is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. Evolus can also be reached via phone at (949) 284-4555 and via email at [email protected]. Learn More on Rui Avelar's contact information.

Has Rui Avelar been buying or selling shares of Evolus?

Rui Avelar has not been actively trading shares of Evolus during the last quarter. Most recently, Rui Avelar sold 27,603 shares of the business's stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $13.92, for a transaction totalling $384,233.76. Following the completion of the sale, the insider now directly owns 372,288 shares of the company's stock, valued at $5,182,248.96. Learn More on Rui Avelar's trading history.

Who are Evolus' active insiders?

Evolus' insider roster includes Rui Avelar (Insider), Vikram Malik (Director), and David Moatazedi (Insider). Learn More on Evolus' active insiders.

Are insiders buying or selling shares of Evolus?

During the last twelve months, Evolus insiders bought shares 1 times. They purchased a total of 174,967 shares worth more than $1,296,505.47. During the last twelve months, insiders at the sold shares 16 times. They sold a total of 2,024,564 shares worth more than $16,771,881.85. The most recent insider tranaction occured on June, 5th when insider David Moatazedi sold 155,278 shares worth more than $2,006,191.76. Insiders at Evolus own 6.1% of the company. Learn More about insider trades at Evolus.

Information on this page was last updated on 6/5/2024.

Rui Avelar Insider Trading History at Evolus

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/19/2024Sell27,603$13.92$384,233.76372,288View SEC Filing Icon  
8/16/2023Sell2,211$10.27$22,706.97353,386View SEC Filing Icon  
8/10/2021Sell14,293$11.18$159,795.74209,810View SEC Filing Icon  
1/7/2020Sell39,442$10.71$422,423.8270,802View SEC Filing Icon  
See Full Table

Rui Avelar Buying and Selling Activity at Evolus

This chart shows Rui Avelar's buying and selling at Evolus by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Evolus Company Overview

Evolus logo
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Read More

Today's Range

Now: $10.64
Low: $10.53
High: $10.87

50 Day Range

MA: $12.36
Low: $10.64
High: $13.70

2 Week Range

Now: $10.64
Low: $7.07
High: $15.43

Volume

574,119 shs

Average Volume

404,648 shs

Market Capitalization

$666.06 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.32